Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: J Orthop Res. 2011 Nov 15;30(6):927–933. doi: 10.1002/jor.22008

Figure 5.

Figure 5

Relationship between VL:VM activation ratio and VM activation delay in (A) pain-free controls and all PF pain (PFP) subjects, and (B) PFP subjects classified into normal tracking and maltracking groups. The regression line represents a significant relationship (R2 = 0.76, p = 0.001) in maltracking PFP subjects. No significant relationships existed between VL:VM activation ratio and VM activation delay in pain-free controls (R2 = 0.06, p = 0.399), all PFP subjects (R2 = 0.01, p = 0.548), or normal tracking PFP subjects (R2 = 0.01, p = 0.659).